|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.250 - 0.285|
|52 Week Range||0.160 - 0.890|
|PE Ratio (TTM)||-0.52|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysis Company to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia. SOUTH SAN FRANCISCO, ...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced ...
Primary Endpoint- Early Progression Free Survival data favors CA4P CA4P continues to be safe and well-tolerated Next interim analysis expected in September. SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017-- ...
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today provided ...
Recruitment rate significantly increased following initial positive interim analysis Interim data read-outs expected in August, September and November. SOUTH SAN FRANCISCO, Calif., Aug. 01, 2017-- Mateon ...
Two patients of four achieved a complete remission No dose-limiting toxicities observed. SOUTH SAN FRANCISCO, Calif., July 31, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular ...
Zacks.com featured highlights: Mateon Therapeutics, Emerge Energy Services, Cobalt International Energy and Inpixon
NEW YORK, Dec. 8, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Mateon Therapeutics, Inc. (OTCQX: MATN), ...
Mateon Therapeutics Inc (NASDAQ:MATN) has spent the last few months petitioning its shareholders for approval of a reverse split. The company is trading well below the NASDAQ mininium bid threshold, and the split was targeted at raising the company’s price per share, in an attempt to re-comply with requirements and maintain its listing. Despite management’s […]